読み込み中
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
前日終値
$0.2379
−$0.0001 · -0.04%
時間外
$0.2385
+$0.0006 · +0.25%
10月12日 17:27 ET
日中の時刻はETです。市場データは遅延する場合があります。
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
日中レンジ
現在 $0.2379
52週レンジ
現在 $0.2379
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
72
割安
センチメント
46
まちまち
リスク
72
高リスク
モメンタム
45
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
日中レンジ
現在 $0.2379
52週レンジ
現在 $0.2379
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1032.5万 USD | 281.6万 USD | 2104.9万 USD | 1353.5万 USD | 1014.1万 USD |
| 売上原価 | 286.6万 USD | — | — | — | — |
| 粗利益 | 745.9万 USD | 281.6万 USD | 2104.9万 USD | 1353.5万 USD | 1014.1万 USD |
| 研究開発 | 1.14億 USD | 1.07億 USD | 8815.3万 USD | 5981.9万 USD | 4495.4万 USD |
| 販売・一般管理 | 3198.8万 USD | 2955.9万 USD | 2549.2万 USD | 2035.2万 USD | 1382.8万 USD |
| 営業費用 | 1.43億 USD | 1.38億 USD | 1.15億 USD | 8017.1万 USD | 5878.2万 USD |
| 受取利息 | 881.6万 USD | 1206.5万 USD | 799.9万 USD | 159.1万 USD | 1.6万 USD |
| 支払利息 | 276.9万 USD | 365.3万 USD | 375.9万 USD | 117.6万 USD | — |
| 減価償却費と償却費 | 286.6万 USD | 410.8万 USD | 536.1万 USD | 513.7万 USD | 332.8万 USD |
| 営業利益 | −1.36億 USD | −1.35億 USD | −9345.8万 USD | −6663.6万 USD | −4864.1万 USD |
| 純利益 | −1.3億 USD | −1.27億 USD | −8921.8万 USD | −6622.1万 USD | −4862.5万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$1.00
上昇余地（320.34%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI134.49万0.00%2.3兆 USD0.03%$381.57-0.10%
Vanguard Extended Market ETFVXF48.58万0.00%954億 USD0.05%$233.52-0.63%
iShares Micro-Cap ETFIWC3.78万0.00%13.17億 USD0.60%$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM2万0.01%1.16億 USD0.73%$15.8484-0.58%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
